Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission RatesBram Verstockt, Marc Ferrante, Erwin Dreesen et al.|Journal of Crohn s and Colitis|2019Cited by 123
Immunogenicity is not the driving force of treatment failure in vedolizumab‐treated inflammatory bowel disease patientsNathalie Van den Berghe, Ann Gils, Marc Ferrante et al.|Journal of Gastroenterology and Hepatology|2018Cited by 34
Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab ConcentrationsNathalie Van den Berghe, Debby Thomas, Bram Verstockt et al.|Journal of Crohn s and Colitis|2020Cited by 15
Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn’s DiseaseNathalie Van den Berghe, Paul Declerck, Bram Verstockt et al.|Clinical Gastroenterology and Hepatology|2021Cited by 7
Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn’s diseaseNathalie Van den Berghe, Debby Thomas, Dahham Alsoud et al.|Therapeutic Advances in Gastroenterology|2023Cited by 7